

CURRICULUM VITAE

Lixian Zhong, Ph.D.

*Department of Pharmaceutical Sciences, Rangel School of Pharmacy, Texas A&M University,
College Station, TX 77843, USA. Office Phone: 979-436-0193, Email: zhong@tamu.edu*

EDUCATION

2004 - 2011	Ph.D. in Pharmacology, Duke University
2008 - 2010	M.A. in Economics, Duke University
1999 - 2003	B.S. in Biological Sciences, Peking University, China

PROFESSIONAL EXPERIENCE/APPOINTMENTS

Assistant Professor (2015 - present)	School of Pharmacy, Texas A&M University, College Station, TX
Adjunct Assistant Professor (2018 - present)	Pharmacy, Academic Institute Houston Methodist, Houston, TX
Assistant Clinical Professor (2014 - present)	School of Pharmacy, University of California, San Francisco, CA
Senior Analyst (2013 - 2015)	Corporate Strategy/Market Access, Biogen, Cambridge, MA
Post-doctoral Fellow (2011 - 2013)	School of Pharmacy, University of California, San Francisco, CA
Summer Intern (2010)	World Health Organization (WHO), Geneva, Switzerland
Graduate Research Assistant (2005 – 2011)	Pharmacology and Molecular Cancer Biology, Duke University, Durham, NC

PUBLICATIONS

Journal Publications (peer-reviewed)

*as Corresponding Author, student authorships are indicated with “_____”

Research Article

1. Berrios K., Burum A., Jeong E., & **Zhong L.*** (2022). Is Adding Ribociclib to Fulvestrant Cost-Effective in Treating Post-Menopausal Women with HR+/ HER2 Advanced Breast Cancer - a U.S. Payer Perspective Cost-Utility Analysis. *Journal of Managed Care & Specialty Pharmacy*, in-press.
2. Ory, M., Lee, S., Dahlke, D. V., Pardo, N., **Zhong, L.**, McCord, C.E., Alonzo, J.P. & Smith, M., L. (2022). Physicians' Interest in Different Strategies for Supporting Pain Management and Opioid Prescribing: A Cross-Sectional Study. *Journal of Opioid Management*, in-press.

3. Ionova L., Vuong W., Sandoval O., Fong J., Vu V., **Zhong L.**, & Wilson L. (2022). Cost-Effectiveness Analysis of Atezolizumab versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA. *Clinical Drug Investigation*, 42(6), 491-500.
4. Tran A.T., Rizk E., Haas E.M., Naufal G., **Zhong L.**, & Swan J.T. (2022). Real-World Data on Liposomal Bupivacaine and Inpatient Hospital Costs after Colorectal Surgery. *Journal of Surgical Research*, 272, 175-183.
5. Chan A., Dang C., Wisniewski J., Weng X., Hynson E., **Zhong L.**, & Wilson L. (2022). A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma. *American Journal of Clinical Oncology*, 45(2), 66-73.
6. Dong L., Lin S., **Zhong L.**, Nian D., Li Y., Wang R., Zhou W., Weng X., & Xu X. (2022). Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients with Brain Metastases: A United States-Based Cost-Effectiveness Analysis. *Clinical Breast Cancer*, 22(1), e21-e29
7. Chen Y., Wu L., Hernández-Muñoz J.J., Miller M.J., Pope M., Huyan Y., & **Zhong L.*** (2022). The Economic Burden of Systemic Sclerosis—A Systematic Review. *International Journal of Rheumatic Diseases*, 25(2), 110-120.
8. Li Y., Lin S., **Zhong L.**, Luo S., Huang X., Huang X., Dong L., Xu X., & Weng X. (2021). Is Olaparib Cost-Effective in Metastatic Castration-Resistant Prostate Cancer Patients with at Least One Favorable Gene Mutation in BRCA1, BRCA2 or ATM? *Pharmacogenomics*, 22(13), 809-819.
9. Narsipur, N., Bulla, S., Yoo, C., Do, B., Tran, K., **Zhong, L.**, & Wilson, L. (2021). Cost-Effectiveness of Adding Daratumumab or Bortezomib to Lenalidomide Plus Dexamethasone for Newly Diagnosed Multiple Myeloma. *Journal of Managed Care & Specialty Pharmacy*, 27(12), 1691-1702.
10. Smith, M. L., **Zhong, L.**, Lee, S., Towne, S. D. Jr., & Ory, M. G. (2021). Effectiveness and Economic Impact of a Diabetes Education Program among Adults with Type 2 Diabetes in South Texas. *BMC Public Health*, 21(1), 1-12.
11. Jeong, E., Wang, C., Wilson, L., & **Zhong, L.*** (2021). Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women. *Frontiers in Oncology*, 11:658054.
12. Hernández-Muñoz, J., Chandni, K.R., **Zhong, L.**, Alonzo, A.P. & Sprenger, L. (2021). Impact of a Pharmaceutical Care Incentive Program on the Asthma Medication Ratio among Pediatric Patients with Persistent Asthma Enrolled in a Medicaid Program. *Journal of Managed Care & Specialty Pharmacy*, 27(6), 714-723.
13. Le, V., **Zhong, L.**, Narsipur, N., Hays, E., Tran, D. K., Rosario, K. & Wilson, L. (2021). Cost-Effectiveness of Ribociclib + Endocrine Therapy versus Placebo + Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer. *Journal of Managed Care & Specialty Pharmacy*, 27(3), 327-338.
14. Lin S., Luo S., **Zhong L.**, Lai S., Zeng D., Rao X., Huang P., & Weng X. (2020). Cost-Effectiveness of Atezolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer. *International Journal of Clinical Pharmacy*, 42(4), 1175-1183.

15. Weng X., Luo S., Lin S., **Zhong L.**, Li M., Xin R., Huang P., & Xu X. (2020). Cost-Utility Analysis of Pembrolizumab versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer with Different PD-L1 Expression Levels. *Oncology Research*, 28(2), 117-125.
16. **Zhong L.***, Pope M., Shen Y., Hernandez J.J., & Wu L. (2019). Prevalence and Incidence of Systemic Sclerosis: A Systematic Review and Meta-Analysis. *International Journal of Rheumatic Diseases*, 22(12), 2096-2107.
17. Tang J., **Zhong L.**, Paoli C., Paciorek A., Carroll P., & Wilson L. (2019). Longitudinal Comparison of Patient-level Outcomes and Costs across Prostate Cancer Treatments with Urinary Problems. *American Journal of Men's Health*, 13(2), 1-9.
18. Wu L. & **Zhong L.*** (2019). Budget Impact Analysis of Niraparib and Olaparib for Maintenance Treatment of Platinum-sensitive, Recurrent Ovarian Cancer in the US. *Journal of Medical Economics*, 22(2), 187-195.
19. **Zhong L.***, Tran A.T., Tomasino T., Nugent E., & Smith J.A. (2018). Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum Sensitive, Recurrent Ovarian Cancer. *Journal of Managed Care & Specialty Pharmacy*. 24(12), 1219-1228.
20. Wilson L., Loucks A., Gipson G., **Zhong L.**, Bui C., Miller E., Owen M., Pelletier D., Goodin D., Waubant E., & McCulloch C. (2015). Patient Preferences for Attributes of Multiple Sclerosis Disease-Modifying Therapies: Development and Results of a Ratings-Based Conjoint Analysis. *International Journal of MS Care*, 17(2), 74-82.
21. Wilson L., Loucks A., Bui C., Gipson G., **Zhong L.**, Schwartzburg A., Crabtree E., Goodin D., Waubant E., & McCulloch C. (2014). Patient Centered Decision Making: Use of Conjoint Analysis to Determine Risk Benefit Trade-Offs for Preference-Sensitive Treatment Choices. *Journal of the Neurological Sciences*. 344(1-2), 80-87.
22. Wilson L., Tang J., **Zhong L.**, Balani G., Gipson G., Xiang P., Yu D., & Srinivas S. (2014). New Therapeutic Options in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Can Cost-Effectiveness Analysis Help in Treatment Decisions? *Journal of Oncology Pharmacy Practice*, 20(6), 417-425.
23. **Zhong L.**, Pon V., Srinivas S., Nguyen N., Frear M., Kwon S., Gong C., Malmstrom R., & Wilson L. (2013). Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis. *PLoS One*, 8(5), e64275.
24. Schwartz N.U., **Zhong L.**, Bellemer A., & Tracey W.D. (2012). Egg Laying Decision in *Drosophila* are Consistent with Foraging Costs of Larval Progeny. *PLoS One*, 7(5), e37910.
25. **Zhong L.[¶]**, Bellemer B.[¶], Yan H., Honjo K., Robertson J., Hwang R.Y., Pitt G.S., & Tracey W.D. (2012). Thermosensory and Nonthermosensory Isoforms of *Drosophila Melanogaster* TRPA1 Reveal Heat-Sensor Domains of a ThermoTRP Channel. *Cell Reports*, 1(1), 43-55. (¶ authors contributed equally)
26. **Zhong L.[¶]**, Hwang R.Y.[¶], & Tracey W.D. (2010). Pickpocket is a DEG/ENaC Protein Required for Mechanical Nociception in *Drosophila* Larvae. *Current Biology*, 20(5), 429-434. (¶ authors contributed equally)
27. **Zhong L.[¶]**, Hwang R.Y.[¶], Xu Y., Johnson T., Zhang F., Deisseroth K., & Tracey W.D. (2007). Nociceptive Neurons Protect *Drosophila* Larvae from Parasitoid Wasps. *Current Biology*, 17(24), 2105-2116. (¶ authors contributed equally)

Submitted Manuscripts

1. **Zhong L.**,* Huyan Y., Andreyeva E., Smith, M.L., Han G., Carpenter K., Towne S.D., Jani S. J., Preston V.A., & Ory M.G. Predicting high-cost diabetes patients: An analysis of commercially-insured population. Submitted to *Medical Care*

Abstracts and Poster Presentations

1. Ionova Y., **Zhong L.**, Ma Y., Wilson L. Health Equity Considerations in Minority Groups with Type 1 and 2 Diabetes in the COVID-19 era: Care Utilization and Costs. International Society of Pharmacoeconomics and Outcomes Research Annual Conference, May 15-18, 2022
2. **Berrios K.**, **Burum A.**, Jeong E., **Zhong L.*** Is Adding Ribociclib to Fulvestrant Cost-Effective in Treating Post-Menopausal Women with HR+/ HER2- Advanced Breast Cancer - a US Payer Perspective Cost-Utility Analysis. International Society of Pharmacoeconomics and Outcomes Research Annual Conference, May 15-18, 2022
3. **Berrios K.**, **Zhong L.**, **Burum A.**, & Jeong E. Is Adding Ribociclib to Fulvestrant Cost-effective in Treating Post-menopausal Women with HR+/ HER2- advanced Breast Cancer in the U.S.? American Pharmacists Association (APhA) Annual Meeting, March 18-21, San Antonio, TX
4. Ionova Y., **Zhong L.**, Ma Y., & Wilson L. A comparison of pre-COVID and post-COVID Hospitalizations for Diabetes related Amputation Academy of Orthotists and Prosthetists (AAOP) 48th Annual Meeting & Scientific Symposium, March 2-5, 2022, Atlanta, GA
5. **Berrios K.**, **Burum A.**, Jeong E., & **Zhong L.***. Is Adding Ribociclib to Fulvestrant Cost-Effective in Treating Post-Menopausal Women with HR+/ HER2- Advanced Breast Cancer in the United States? ASHP Midyear Conference. Dec 2021. [Virtual]
6. Alonzo, J., Ozmetin, J., McMaughan, D., **Zhong, L.**, Lee, S., Saldivar, I., Tomaszewski, L. "Leveraging innovation and telehealth to address hospital closure in rural Texas, a moonshot initiative." American Public Health Association Annual Meeting, Oct 2021.
7. **Dawamne T.** & **Zhong L.*** (2021) Neonatal Abstinence Syndrome Incidence Rate, Clinical Characteristics & Healthcare Resource Utilization in Texas during 2006-2017. International Society of Pharmacoeconomics and Outcomes Research Annual Conference, May 17-20, 2021. [Virtual]
8. Tran A.T., Rizk E., Haas E.M., Naufal G., **Zhong L.**, & Swan J.T. Liposomal Bupivacaine and Inpatient Hospital Costs after Colorectal Surgery. International Society of Pharmacoeconomics and Outcomes Research Annual Conference, May 17-20, 2021. [Virtual]
9. Dong L., Nian D., Huang Y, Lin S, **Zhong L.**, & Xu X. Evaluation of Tucatinib for HER2-Positive Breast Cancer Patients with Brain Metastases- A United States-Based Cost-Effectiveness Analysis. International Society of Pharmacoeconomics and Outcomes Research Annual Conference, May 17-20, 2021. [Virtual]
10. Smith, M. L., **Zhong, L.**, Krajcinovic, I., Lewis, T., Elder, K., Nottenson, T., & Rott, E. (2021). Long-term benefits of chronic disease self-management program (CDSMP) on biometric measures among employed hospitality workers with chronic conditions. Presented at the American Public Health Association Annual Meeting, October 24-27, 2021. Denver, CO. [virtual]

11. Jeong E., Nguyen V., Ngo H., Gu D., **Zhong L.*** Evaluating the cost-effectiveness of adding ribociclib to endocrine therapy for patients with HR-positive, HER2-negative advanced breast cancer among premenopausal or perimenopausal women. Academy of Managed Care Pharmacy Annual Conference, 2020
12. Jeong E., Tomasino T., Sprenger L., Alonzo J., **Zhong L.**, Hernandez J.J. Effect of an Asthma-Related Educational Intervention Targeting Pharmacies in a Managed Care Organization CHIP/Medicaid Network in the Provision of Pharmaceutical Care Incentive Programs for Asthma and Patients' Process and Outcomes Measures. Academy of Managed Care Pharmacy Annual Conference, 2020
13. Jeong E., Nguyen V., Ngo H., Gu D., **Zhong L.*** Cost-effectiveness of ribociclib plus endocrine therapy in treating premenopausal or perimenopausal women with HR+, HER2- advanced breast cancer in the United States. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Conference, 2020
14. Chen Y., Wu L., Miller M., Hernandez J., Pope M., & **Zhong L.*** (2019) A Systematic Review of the Economic Burden of Systemic Sclerosis. ISPOR 22nd Annual International Conference, May 18-22, 2019, New Orleans, LA.
15. Duong T.W., Tran A.T., Alonzo J., & **Zhong L.*** (2019) Pharmacoeconomic Evaluation of Naloxone Distribution for the Prevention of Opioid Overdose Fatalities: A Systematic Review. ISPOR 22nd Annual International Conference, May 18-22, 2019, New Orleans, LA.
16. Tomasino T.A., Jeong E., Bermudez S., Gu D., Sharma P., Alonzo J., **Zhong L.**, Sprenger L., Garcia T., Hernandez J. (2019) Assessment of Pharmacists' Confidence and Knowledge of Pediatric Asthma and a PCI Reimbursement Program through Targeted Point-of-Sale Intervention Training, Texas Society of Health-System Pharmacists (TSHP) Annual Conference, April 12-14, 2019, Frisco, TX
17. **Zhong L.***, Parambil A., Patel N., & Duong T. (2019) Prescription Drug Price Variation among Community Pharmacies in Texas. 2019 Health Care Systems Research Network Conference. April 8 - 10, 2019. Portland, Oregon.
18. Duong T.W., Tran A.T., Alonzo J., & **Zhong L.*** (2019) Pharmacoeconomic Evaluation of Naloxone Distribution for the Prevention of Opioid Overdose Fatalities: A Systematic Review. 2019 Health Care Systems Research Network Conference. April 8 - 10, 2019. Portland, Oregon.
19. **Zhong L.**, Smith, M. L., Lyu N., Davlasheridze, M., Alonzo, J. P., & Ory, M. G. (2019). Opioid Misuse-related Health Care Resource Utilization and Costs in Texas. 2019 Health Care Systems Research Network Conference. April 8 - 10, 2019. Portland, Oregon.
20. Wu L. & **Zhong L.*** (2019) Budget Impact of Adopting PARP Inhibitors as Maintenance Therapy for Patients with Recurrent Ovarian Cancer. 2019 Health Care Systems Research Network Conference. April 8 - 10, 2019. Portland, Oregon.
21. **Zhong L.**, Pope M., Shen Y., Hernandez J., & Wu L. Epidemiological Burden of Systemic Sclerosis – A Systematic Review. (2019) Health Care Systems Research Network Conference. April 8 - 10, 2019. Portland, Oregon.
22. **Zhong L.**, Smith, M.L., Lyu L., N., Davlasheridze, M., Alonzo, J. P., & Ory, M. G. (2019). Opioid Misuse-related Health Care Resource Utilization and Costs in Texas. Academy of Managed Care Pharmacy Annual Conference, March 25-28, 2019. San Diego, CA.

23. Wu L. & **Zhong L.** (2019) Budget Impact of Adopting PARP Inhibitors as Maintenance Therapy for Patients with Recurrent Ovarian Cancer. Academy of Managed Care Pharmacy Annual Conference, March 25-28, 2019. San Diego, CA.
24. Duong T.W., Tran A.T., Alonzo J., & **Zhong L.*** (2019) Pharmacoeconomic Evaluation of Naloxone Distribution for the Prevention of Opioid Overdose Fatalities: A Systematic Review. Academy of Managed Care Pharmacy Annual Conference, March 25-28, 2019. San Diego, CA.
25. Smith, M. L., Ory, M. G., Herrera-Venson, A., **Zhong, L.**, Lee, S., Towne, S. D. Jr., Kulinski, K. P., Cameron, K., & Lorig, K. (2019) Combating the opioid crisis with non-pharmacological pain self-management programs. Poster presented at the American Academy of Health Behavior Conference, March 10-13, 2019. Greenville, SC.
26. Smith, M. L., **Zhong, L.**, Flores, S., Flores, J. R., Towne, S. D. Jr., Lee, S., & Ory, M. G. (2019). Effectiveness of a diabetes education program among adults with Type 2 diabetes living at the Texas-Mexico border. Poster presented at the American Academy of Health Behavior Conference, March 10-13, 2019. Greenville, SC.
27. Duong T.W., Tran A.T., & **Zhong L.*** (2018) Pharmacoeconomic evaluation of naloxone distribution for the prevention of opioid overdose fatalities: a systematic review. ASHP Midyear Clinical Meeting Anaheim, CA, December 2-6, 2018
28. Wu L. & **Zhong L.*** (2018) Budget Impact Analysis of Niraparib and Olaparib as Maintenance Treatment of Platinum-Sensitive, Recurrent Ovarian Cancer in the US. ASHP Midyear Clinical Meeting Anaheim, CA, December 2-6, 2018
29. Hutchison R.W., Lin S., **Zhong L.**, Pekarek K.J., McMaughan D. (2018) Assessing Learning Needs in Chronic Pain Management Curriculum. the 4th Annual Interprofessional Education and Research Symposium (IPER 4). Bryan, Texas. November 1, 2018.
30. **Zhong L.***, Tran A.T., & Tomasino T. (2018) Cost-effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum Sensitive, Recurrent Ovarian Cancer. ISPOR 23rd Annual International Meeting, Baltimore MD, May 19-23, 2018.
31. Wu L., & **Zhong L.*** (2018) Budget Impact Analysis of Niraparib and Olaparib as Maintenance Therapy for Platinum-Sensitive, Recurrent Ovarian Cancer in the US. ISPOR 23rd Annual International Meeting, Baltimore MD, May 19-23, 2018.
32. Hutchison R.W., Lin S., **Zhong L.**, Pekarek K.J., McMaughan D. (2018) Improving Chronic Pain Management Curriculum Through New Health Care Professional Feedback. Transformational Teaching & Learning Conference, Texas A&M University, College Station, Tx, April 18, 2018
33. **Zhong L.***, Pope M. & Wu L. (2017) Epidemiology and Economic Burden of Systemic Sclerosis – A Systematic Review. The 3rd Annual Interprofessional Education and Research Symposium (IPER 3) September 28, 2017, Bryan, Texas
34. Tran AT., Tomasino T., & **Zhong L.*** (2017) Cost-effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive, Recurrent Ovarian Cancer. The 3rd Annual Interprofessional Education and Research Symposium (IPER 3) September 28, 2017, Bryan, Texas
35. Wu L. & **Zhong L.*** Budget Impact Analysis of Niraparib and Olaparib as Maintenance Therapy for Platinum-Sensitive, Recurrent Ovarian Cancer in the US. (2017) The 3rd Annual

Interprofessional Education and Research Symposium (IPER 3) September 28, 2017, Bryan, Texas.

36. **Zhong L.***, Pope M. Wu L. (2017) Epidemiology and Economic Burden of Systemic Sclerosis – A Systematic Review. ISPOR 22nd Annual International Meeting, Boston, MA 2017.
37. Tran A.T., Tomasino T., & **Zhong L.*** (2017) Cost-effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive, Recurrent Ovarian Cancer. American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting, Orlando FL 2017 .
38. **Zhong L.***, Douglas C., Hutchison R.W., Potter D. (2016) Utilization Pattern of Prescription Pain Medication among Adults with Diabetes Mellitus. ISPOR 21th Annual International Meeting, Washington DC.
39. Ting J., **Zhong L.**, Petrillo J., Niu X., Lee A., Sarda S. (2015) Patient-Reported Outcome Measures for Multiple Sclerosis Phase IV Clinical Trials: A Systematic Review. ISPOR 20th Annual International Meeting, Philadelphia
40. **Zhong L.**, Niu X., & Sarda S. (2014) Health-Related Quality of Life Instruments Used in Multiple Sclerosis Clinical Trials: A Systematic Review. Annual Meeting – the Consortium of Multiple Sclerosis Centers, Dallas
41. Kappos L., Fox R.J., Gold R., Kita M., Phillips J. T., Sarda S.P., Zhong L., Niecko T., Kurukulasuriya N. C., & Giovannoni G. (2014) Effect of Delayed-Release Dimethyl Fumarate on Health-Related Quality of Life in Relapsing–Remitting Multiple Sclerosis (RRMS) Patients According to Prior Therapy: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies. Annual Meeting – American Academy of Neurology, Philadelphia
42. Kappos L., Fox R.J., Gold R., Kita M., Phillips J.T., Sarda S.P., **Zhong L.**, Niecko T., Kurukulasuriya N.C., & Giovannoni G., Delayed-release dimethyl fumarate and health-related quality of life (HRQoL) in relapsing-remitting multiple sclerosis (RRMS) patients according to prior therapy: integrated analysis of DEFINE and CONFIRM. (2014) the 2014 Joint Congress of European Neurology, Istanbul, Turkey
43. Wilson L.S., Tang J., **Zhong L.**, Balani G., Gipson G., Xiang P., Yu D., & Srinivas S., New Therapeutic Options in the Metastatic Castration-Resistant Prostate Cancer: Can Cost-effectiveness Analysis Help in Treatment Decision? (2013) University of California, San Francisco Prostate Cancer Research Retreat 2013, San Francisco
44. Wilson L.S., Loucks A., Gipson G., Miller E., **Zhong L.**, Azarraga M., Gonzalez C., Owen M., Bui C., Waubant E., & McCulloch C. (2012) Patient preferences for attributes of disease-modifying multiple sclerosis therapies: preliminary results of a conjoint analysis European Committee for Treatment and Research in Multiple Sclerosis, Lyon, France
45. Wilson L.S. Loucks A. Bui C.T. Gipson G. **Zhong L.** Tang J. Goodin D. (2013) Owen M. Waubaunt E. Cree B. Schwartzburg A. Miller E. Macedo A. Scott D McCulloch C.E. Patient preferences for attributes of disease modifying Therapies: Results of a choice based conjoint analysis International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting, New Orleans
46. Tang J., **Zhong L.**, Gipson G., Balani G., Xiang P., Yu D., Srinivas S., & Wilson L. (2013) New therapeutic options in metastatic castration-resistant prostate cancer (mCRPC): Can cost-effectiveness analysis help in treatment decision? Society for Medical Decision Making (SMDM) annual conference Baltimore

47. Wilson L.S., **Zhong L.**, Pon V., Srinivas S., Frear M., Nguyen N., Gong C., Kwon S., Malmstrom R., & Loucks A. (2012) Cost-effectiveness Analysis of New Treatments for Metastatic Castration-resistant Prostate Cancer: Does Severity Matter? Poster presentation, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting, Washington DC
48. Lee-Grossman C.W., Saunders W.B., Wilson L.S., & **Zhong L.** (2012) The Population-Based Impact of MS in East Asia Poster presentation: 5th ISPOR Asia Pacific Conference Taipei, Taiwan
49. Wilson L., Basu R., Paoli C.J., Sadetsky N., **Zhong L.**, Cooperberg M., Sanda M., & Carroll P. (2011) Comparative Effectiveness Research as a Health Reform Mechanism: Longitudinal Outcomes and Costs across Treatments for Prostate Cancer, Harvard, America-China health Summit, Cambridge, MA
50. **Zhong L.**, Bellemer, A., Honjo, K., Hwang, R.Y., Tracey, W.D. (2011) A non-thermosensory isoform of *Drosophila melanogaster* TRPA1 is required for thermal nociception. Neurobiology of *Drosophila* Meeting Cold Spring Harbor, NY.
51. Schwartz N.U., **Zhong L.**, Bellemer A., & Tracey W.D. (2012) Egg laying decisions in *Drosophila* depend on the size of the oviposition substrate and are consistent with optimal larval foraging strategies. The Genetic Society of America Conference: 53rd Annual *Drosophila* Research Conference, Chicago, IL.
52. **Zhong L.** & Tracey W.D. (2010) The *Drosophila* TRPA1 Channel Is Required for Thermal and Mechanical Nociception. The Genetic Society of America Conference: 51st Annual *Drosophila* Research Conference, Washington D.C.
53. **Zhong L.**, Tracey W.D. (2009) Pickpocket is a DEG/ENaC Channel Required for Mechanical Nociception. The Genetic Society of America Conference: 50th Annual *Drosophila* Research Conference, Chicago, IL.
54. **Zhong L.**, Tracey W.D. (2009) Distinct classes of thermosensory neuron in the *Drosophila* antennae. EMBO Conference "Assembly and Function of Neural Circuits", Ascona, Switzerland.
55. **Zhong L.**, Hwang R.Y., Johnson T., Xu Y. & Tracey W.D. Optogenetic control of nociception behavior in *Drosophila* larvae. Cold Spring Harbor Neurobiology of *Drosophila* Conference, 2007. Long Island, NY
56. Hwang R.Y., **Zhong L.**, Johnson T., Stearns N., Tracey W.D. (2007) *Drosophila melanogaster* as a model for pain. American Society for Anesthesiologists, San Francisco, CA.
57. Hwang R.Y., Johnson T., **Zhong L.**, Xu Y., Zhang F., Deisseroth K., Tracey W.D. (2007) Optogenetic activation of neurons and behavior in *Drosophila melanogaster* larvae. Society for Neuroscience Meeting, San Diego, CA.
58. Hwang R.Y., **Zhong L.**, Xu Y., Johnson T., Zhang F., Deisseroth K., Tracey W.D. (2007) Nociceptive multidendritic neurons protect *Drosophila* larvae from parasitoid wasps. Society for Neuroscience Meeting, San Diego, CA.
59. Hwang, R.Y., Zhong, L., Johnson, T., Stearns, N., Tracey, W.D. (2007) *Drosophila melanogaster* as a model for pain. American Society for Anesthesiologists, San Francisco, CA.

60. **Zhong L.**, Tracey W.D. (2006) The *Drosophila* mutant oblivious is defective in nociception. The Genetic Society of America Conference: 47th Annual *Drosophila* Conference, Houston, TX.
61. **Zhong L.**, Stearns N.A., Hofhine A.M., Tracey W.D., (2005) Transmembrane Topology of the TRPA channel Painless. Gordon Research Conference on Mechanotransduction & Gravity Signaling in Biological Systems, Briddeford, ME.

PODIUM/INVITED PRESENTATIONS

Submitted Presentations

1. Smith, M. L., Steinman, L. E., Montoya, N. C., Thompson, M., **Zhong, L.**, & Merianos. A. L. (2022). A string of PEARLS: Using a multi-state evaluation to guide program implementation and sustainability. Presented at the National Council on Aging Age+Action Virtual Conference, June 6-8, 2022. [virtual]
2. Wilson L., **Zhong L.**, Ionova Y., Ma Y. COVID-19 Related Changes in outcomes for Type 1 and 2 Diabetes after Delayed Hospital Care. UHG Diabetes Care Journey Working Group Meeting, Feb 8th, 2022 [Virtual]
3. L Wilson, **Zhong L.** Ma Y. Comparison of Incidence, Outcomes and Care Deferrals from COVID-19 on Marginalized Groups with Different Types of Diabetes Risk. PRESTAC Health Equity Collaborative. April 20th, 2021
4. Ionova I., Wilson L., **Zhong L.**, Ma Y. Health Equity Considerations in Minority Groups with Type 1 and 2 Diabetes in the COVID-19 Era: Health Care Utilization and Costs. OptumLabs Partner Ideas Exchange (PIE) Meeting, Dec 8th, 2021[Virtual]
5. **Zhong L.**, Tran AT, Tomasino T, Nugent E, & Smith J. (2019) A Cost-effectiveness Analysis of PARP Inhibitors as Maintenance Therapy for Patients with Recurrent Ovarian Cancer. 2019 Health Care Systems Research Network Conference. April 8th, 2019. Portland, Oregon.
6. **Zhong L.** A&M Collaboratory for Understanding and Reducing Untoward Effects of the Opioid Epidemic, Texas A&M University X-grant Health Science Center Symposium, 8/13/2018, College Station, TX
7. **Zhong L.** Cost-effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum Sensitive, Recurrent Ovarian Cancer. International Cancer Biology and Drug Delivery Conference, 9/18/2017, Philadelphia, PA
8. **Zhong L.**, Srinivas S, Pon V, Nguyen N, Frear M, Kwan S, Gong G, Malmstrom R, Loucks A, Wilson L. (2012) Cost-effectiveness Analysis of New Treatments for Metastatic Castration-resistant Prostate Cancer (mCRPC) European Conference on Health Economics (ECHE 2012), Zurich, Switzerland
9. **Zhong L.** Cost-effectiveness of Treatments for metastatic Castrate-resistant Prostate Cancer, Biogen Global Market Access, 2/6/2012, Weston, MA
10. **Zhong L.**, Tracey W.D. (2009) Distinct classes of thermosensory neuron in the *Drosophila* antennae. Cold Spring Harbor *Drosophila* Neurobiology Meeting, CSHL, NY.

11. **Zhong L.**, Hwang R.Y., Xu Y., Johnson T., Zhang F., Deisseroth K., Tracey W.D. (2007) Nociceptive multidendritic neurons protect *Drosophila* larvae from parasitoid wasps." *Drosophila* Conference on Neurobiology. Cold Spring Harbor, NY.
12. Hwang R.H., Johnson T., **Zhong L.**, Hofhine A., Tracey W.D. (2007) Neuronal circuitry of nociception and pain in *Drosophila*. Janelia Farm Conference. "Insect Behavior: Small Brains, Big Functions."
13. Hwang, R.Y., **Zhong, L.**, Xu, Y., Johnson, T., Zhang, F., Deisseroth, K., Tracey, W.D. (2007) Nociceptive multidendritic neurons protect *Drosophila* larvae from parasitoid wasps. Gordon Research Conference on Mechanosensory Transduction, Biddeford, ME selected for hot topic talk.

Invited Presentations

1. **Zhong L.** Effectiveness and Economic Impact of Diabetes Education Programs. Chinese American Diabetes Association Conference, College Station, Tx. Dec 11th, 2021
2. **Zhong L.** Assessing Outcomes and Values for Health Care Interventions. Medical Scholar Research Pathway Program, Texas A&M University, March 25th, 2021
3. **Zhong L.** Assessing Values Associated with New Pharmacotherapies. Health Services Research Seminar, School of Public Health, Texas A&M University. Nov 14th, 2018, College Station, TX
4. **Zhong L.** Measuring Value in Health Care – Let’s Talk About Outcomes Research, Science Café Talk Series, 9/20/2016, College Station, TX
5. **Zhong L.** Incorporating Clinical, Economic and Humanistic Outcomes in Health Care Value Assessment Rangel College of Pharmacy Research Colloquium, 6/3/2016, College Station, TX
6. **Zhong L.** Cost-effectiveness of Treatments for metastatic Castrate-resistant Prostate Cancer, Hong Kong Community Healthcare and Healthcare Management Forum, 01/14/2012, Hong Kong, China

GRANT/CONTRACT ACTIVITY

Current

Identifying Predictors for Scleroderma Health care utilization and costs in specialty care referral and integrated care models. Funded by Johns Hopkins Medicine/Kaiser Permanente Research Collaborative.

Role: Co-PI

Grant total: \$75,000.

2022-2023

Health in Motion – A pragmatic Clinical Trial with Blue Marble Health. DHHS-NIH-NIA/Blue Marble Health (R44 AG043191-04A1).

Role: Co-I

Grant total: \$2,190,504.

2020-2023

Moonshot Project 4: Testing New Models of Diabetes Self-Management to Improve Population Health: Living with Diabetes. Blue Cross Blue Shield.

Role: Co-I

Grant total: \$1,915,746.

2019-2023

Completed

Evaluating the Impact of Influenza Immunization on the Respiratory Health of US Children. President's Excellence Fund T3 Research Grant, Texas A&M University. \$30,000. 2020-2022

Role: Co-PI

Grant total: \$30,000.

2020-2022

Moonshot Project 2: Tackling Distance: Post Closure Access and Innovative Community Care. Blue Cross Blue Shield Texas.

Role: Co-I

Grant total: \$1,437,400.

2019-2022

Health economic evaluation of public health programs. Center for Population Health and Aging, Texas A&M University.

Role: PI

\$ 20,000.

2019-2020

A&M Collaboratory for Understanding and Reducing Untoward Effect of the Opioid Epidemic. Texas A&M University Health Science Center.

Role: Co-PI

Grant total: \$ 14,500.

2018-2019

Opioid Epidemic's Impact on Older Adults. President's Excellence Fund T3 Research Grant, Texas A&M University.

Role: Co-PI

Grant total: \$30,000.

2018-2020

Effect of an Asthma-Related Educational Intervention Targeting Pharmacies in the Driscoll health Plan Texas CHIP/Medicaid Network in the Provision of Pharmaceutical Care Incentive Programs for Asthma and Patients' Outcomes. The Global Institute for Hispanic Health and Healthy South Texas.

Role: Co-PI.
Grant total: \$25,000.
2018-2020

Radical Innovation in the Healthcare Industry. Mays Business School Grand Challenge Grants.
Role: Co-PI
Grant total: \$15,000.
2018-2019.

Pending:

A retrospective pre and post study assessing the impact of a standardized pharmacy led culture review process. Merck Investigator Studies Program.
Role: Co-I
Grant total: \$156,750

Integration of clinical decision support tools and telehealth technology for chronic disease management and polypharmacy in an interprofessional pharmacogenomic clinic and registry. NIH. RFA-HG-20-036 Advancing Genomic Medicine Research (R01)
Role: Co-I
\$3,716,851

Unfunded:

Validation of an interdisciplinary pharmacogenomics care model for improved healthcare outcomes and reduced healthcare costs in primary care settings. NIH. RFA-HG-20-048. Investigator-Initiated Research on Genetic Counseling Processes and Practices (R01)
Role: Co-I
\$2,844,772
2021

Opioid related drug adverse events among the geriatric population. Community Pharmacy Foundation.
Role: PI
\$41,555
2020

Systematic review of registered clinical trials for PARP-inhibitor combination treatments in prostate cancer. The Pfizer Foundation.
Role: PI
\$75,000
2020

Understanding, predicting, and preventing opioid misuse through innovative technologies and care models. President's Excellence Fund X-grant.

Role: Co-Investigator

\$500,000.

2019

Assessing the real-world outcomes of SGLT2 inhibitors in patients with T2DM. American Association of Colleges of Pharmacy.

Role: PI

\$11,000

2018

Opioid Overdose Education and Naloxone Administration & Distribution (OEND). Centers for Disease Control and Prevention.

Role: Co-I.

2018

Prevention Research Center. Center for Disease Control and Prevention (RFA-DP-19-001, Health Promotion and Disease Prevention Research Centers).

\$3,750,000

Role: Co-I

2018

Clinical-Community Collaboration for Opioid Prevention and Education (C3OPE). Centers for Disease Control and Prevention (RFA-CE-18-006, Research Grants for the Primary or Secondary Prevention of Opioid Overdose (R01)).

Role: Co-I.

\$2,249,999

2018

Transdisciplinary Opioid Research Collaboratory (TORC) at Texas A&M University. President's Excellence Fund X-grant.

Role: Co-PI

\$500,000.

2018

Mapping Disease Burden and Risk Factors for Acute Kidney Injury Hospitalization in Medically Underserved Populations – A Texas Statewide Multi-year Study. PESCA grant, Texas A&M University.

Role: PI

\$10,000.

2018

Investigate the outcomes associated with novel ovarian cancer treatment options, niraparib vs. olaparib in real world clinical setting. The Discovery Foundation.

Role: PI
\$50,000
2018

Creating the Framework for a Regional Outpatient Antimicrobial Stewardship Program Using Real-Time Health Information Exchange. The Global Institute for Hispanic Health and Healthy South Texas.

Role: Co-PI
\$25,000
2018

Impact of opioid pandemic on Medicaid population in South Texas. The Global Institute for Hispanic Health and Healthy South Texas.

Role: PI
\$25,000
2018

To Help Diabetes Patients with a New Class of Medication in a Real-world Clinical Setting. PESCA Grant Program. Texas A&M University

Role: Principal Investigator.
\$10,000
2016

Assessing the Outcomes with SGLT2 Treatment across Race and Ethnicity in Patients with Type 2 Diabetes. AstraZeneca Request for Proposal.

Role: Co-PI
\$190,000
2016

Assessing the Real-world Outcomes of SGLT2 inhibitors in Patients with T2DM. AACP New Investigator Award.

\$10,000
Role: PI
2016

Optimizing Post-Amputation Pain Management: Functional Synergy Among Opioid-, NMDA- and α_2 – Receptors. NIH (PAR-14-225, Clinical Evaluation of Adjuncts to Opioid Therapies for the Treatment of Chronic Pain (R01)).

Role: Co-I
\$1,019,111
2016

Current Treatment Paradigm and Unmet Medical Needs in Treating Chronic Neuropathic Pain in the United States: A Call for New Medical Strategy. PESCA Grant Program. Texas A&M University.

Role: PI

\$25,000

2015

PATENTS

Co-Inventor: Methods and compositions for the identification of insect repellent compounds.

Status: Issued (No.:8017316; Issue Date: 9/13/2011)

AWARDS and HONORS

- 2022 **Recipient.** Graduate Teacher of the Year, Rangel College of Pharmacy, Texas A&M University
- 2021 **Recipient.** *OptumLabs* Health Equity Research Proposal Award. Proposal title: Health equity considerations in racial/ethnic minority groups in the COVID-19 era: Comparison of Incidence, outcomes and care deferrals impacts from COVID-19 on marginalized groups with different types of diabetes risk using claims data (role: Co-PI)
- 2020 **Recipient.** *Academy of Managed Care Pharmacy* International Annual Conference Gold Ribbon Award. (Authorship: Jeong E., Nguyen V., Ngo H., Gu D., **Zhong L.***, *corresponding author)
- 2019 **Recipient.** *OptumLabs* Data Warehouse Proposal Award (Role: Co-I)
Proposal title: Predicting Limb Loss in Type 2 Diabetics: Identifying Factors for Preventive Interventions.
- 2018 **Recipient.** Scholarship for Intensive Writing in Research, Texas A&M University
- 2016 **First Place.** 2016 College of Pharmacy Research Colloquium, Texas A&M University Health Science Center
- 2012 **Recipient.** Best Population Science/Outcomes Research Award, University of California, San Francisco

- 2011-2013 **Recipient.** University of California, San Francisco/ Biogen HEOR Fellowship
- 2010 **Recipient.** Global Health Fellow, Sanford School of Public Health, Duke University, Durham, NC
- 2009 **Recipient.** Best Student Talk Award, Department of Neurobiology, Duke University
- 2003 **Recipient.** Sumitomo Corporation Scholarship, Peking University
- 2002, 2003 **Recipient.** Academic Excellence Award, Peking University

TEACHING

PharmD Course Taught, Texas A&M University

- PHAR628 Research Methods and Biostatistics (Course Coordinator & Instructor) Spring 2016, 2017, 2018, 2019, 2020, 2021, & 2022
- PHAR757 Pharmacy Management and Pharmacoeconomics (Course Co-coordinator & Instructor) Spring 2017, 2018, 2019, 2020, 2021, & 2022
- PHAR 873 Pharmacy Professionalism (Instructor) Spring 2020, 2021, & 2022
- PHAR8 785 Independent Study (Research Mentor) Spring 2017, 2019, 2022
- PHAR789 Research Elective Track I (Instructor and research mentor) Spring 2021
- PHAR 656 Health Care System (Instructor) Fall 2016, & 2017
- PHAR 856 Pharmacoeconomics (Instructor) Fall 2016
- PHAR 872 Social Behavioral Aspect of Patient Care (instructor) Fall 2016

PhD Course Taught, Texas A&M University

- PHSC621 Biostatistics (Course Coordinator & Instructor) Spring 2021, & 2022

Teaching Evaluation Scores

Academic Year	Hours of Instruction	Students Impacted	Course Materials Developed	Teaching evaluations
PHAR 628 Research Methods and Biostatistics				
AY 2015-2016	30	113	MS PowerPoint slides, self-paced quizzes (take home exercise), literature-based case studies, problem-based learning activities, PollEveryWhere questions, MS excel spread sheets	4.02
AY 2016-2017	19	121		4.37
AY 2017-2018	32	117		4.67
AY 2018-2019	30	115		4.55
AY 2019-2020	30	111		4.65
AY 2020-2021	30	108		4.73
AY 2021-2022	30	122		4.72
PHAR 757 Pharmacy Management and Pharmacoeconomics				
AY 2016-2017	15	108	MS PowerPoint slides, problem-based learning activities, team-based project and presentation, self-paced quizzes	4.45
AY 2017-2018	15	110		4.52
AY 2018-2019	15	109		4.63
AY 2019-2020	15	103		4.55
AY 2020-2021	15	112		4.76
AY 2021-2022	15	106		4.84
PHSC621 Biostatistics				
AY 2020-2021	45	5	MS PowerPoint slides, flipped classroom discussion, self-paced quizzes, hands-on activities	5
AY 2021-2022	45	6		4.7
PHAR 873 Pharmacy Professionalism				
AY 2019-2020	1	100	MS PowerPoint review slides, PollEveryWhere questions	Not Evaluated
AY 2020-2021	2	100		Not Evaluated
AY 2021-2022	2	100		Not Evaluated
PHAR 872 Social Behavioral Aspect of Patient Care				
AY 2015-2016	2	98	MS PowerPoint slides	Not Evaluated
PHAR856 Pharmacoeconomics				
AY 2016-2017	2	114	MS PowerPoint slides	Not Evaluated
PHAR 656 Health Care System				
AY 2015-2016	2	113	MS PowerPoint slides	Not Evaluated
AY 2016-2017	2	121	MS PowerPoint slides	Not Evaluated
PHAR785 Independent Study (contact hours taught)				
AY 2016-2017	135	2	Research mentoring	Not Evaluated
AY 2018-2019	90	4	Research mentoring	Not Evaluated
AY 2021-2022	90	2	Research mentoring	Not Evaluated

PHAR 789 Research Elective Track I				
AY 2020-2021	1	10	MS PowerPoint slides	Not Evaluated

POST-DOCTORAL/RESIDENTS MENTORING

Postdoctoral

Eunae Jeong: (Aug 2020-May 2021) Cost-effectiveness evaluation of CDK4/6 inhibitors in treating advanced or metastatic breast cancer

Anh Thu Tran: (Aug 2019-May 2020) Real-World Data on Liposomal Bupivacaine and Inpatient Hospital Costs After Colorectal Surgery

Pharmacy Residents

1. Ashly Ibrahim (Aug 2020-Aug 2022) Time of initiation of Remdesivir in laboratory-confirmed COVID-19 patients and its effect on length of stay and mortality
2. Kassandra Closner (Aug 2020-May 2021) Real-world evidence of SGLT2 inhibitors in renal function.
3. Noorulain Momin (Aug 2021-current) Evaluate the clinical outcomes of patients taking ARNI compared to patients taking ACEI/ARBs in heart failure patients in South Texas

GRADUATE/PROFESSIONAL STUDENT RESEARCH MENTORING

Texas A&M University

PhD students

1. Yuqi Zhou (Jan 2022 – May 2022) Health services research data source

PharmD students (13 graduated)

1. Kevin Berrios (May 2020 – present) Cost-effectiveness of Ribociclib in combination with fulvestrant in treating post-menopausal HR+/HER2- advanced or metastatic breast cancer
2. Alexandra Burum (May 2020 – present) Cost-effectiveness of Ribociclib in combination with fulvestrant in treating post-menopausal HR+/HER2- advanced or metastatic breast cancer
3. Eunae Jeong (May 2019 – May 2021) Cost-effectiveness of Ribociclib in combination with an aromatase inhibitor in treating pre/peri-menopausal HR+/HER2- advanced or metastatic breast cancer
4. Jennifer Nwosu (Jan 2021 – present) Cost-effectiveness of CDK4/6 inhibitors in treating breast cancer
5. Vy Nguyen (May 2019 – April 2020) Cost-effectiveness of Ribociclib in combination with an aromatase inhibitor in treating pre/peri-menopausal HR+/HER2- advanced or metastatic breast cancer

6. Hanh Ngo (May 2019 – April 2020) Cost-effectiveness of Ribociclib in combination with an aromatase inhibitor in treating pre/peri-menopausal HR+/HER2- advanced or metastatic breast cancer
7. Tony Duong (May 2018 – May 2020) Pharmacoeconomic evaluation of naloxone in preventing opioid overdose fatalities
8. Ashley Parambil (May 2018 – Aug 2018) Price variations in prescription medications across different pharmacy chains
9. Niraj Patel (May 2018 – Aug 2018) Price variations in prescription medications across different pharmacy chains
10. Heting Zhang (May 2018 – Aug 2018) Outcomes assessment of CDK4/6 inhibitors in treatment breast cancer
11. Se-Jung Hong (May 2018 – Aug 2018) Outcomes assessment of CDK4/6 inhibitors in treatment breast cancer
12. Jacob Sellers (May 2018 – Aug 2018) Outcomes assessment of CDK4/6 inhibitors in treatment breast cancer
13. Taylor Tomasino (May 2017 – May 2018) Cost-effectiveness assessment of PARP inhibitors in treating ovarian cancer
14. Anh Thu Tran (May 2017 – May 2019) Cost-effectiveness assessment of PARP inhibitors in treating ovarian cancer
15. Malinda Pope (May 2016 – April 2017) systematic review of epidemiological and economic burden of systemic sclerosis
16. Lei Wu (May 2016 – April 2018) budget impact analysis of olaparib and niraparib in treating ovarian cancer

Medical students:

1. Anjali Bhatt (Jan 2021 – present): systematic review of cost-effectiveness evidence for CDK4/6 inhibitors in treating breast cancer
2. Tarek Dawamne (Sep 2020 – present) epidemiological and economic trend of neonatal abstinence syndrome in Texas between 2007-2017

Master students (Economics):

1. Danial Kordi (Jan 2017 – May 2017) Characterizing diabetes medication utilization using Medical Expenditure Panel Survey
2. Yiyuan Zhai (Jan 2017 – May 2017) Characterizing diabetes medication utilization using Medical Expenditure Panel Survey
3. Lizhou Xu (Sep 2017 – May 2018) Texas opioid-related health care utilization
4. Ning Lyu (Sep 2017 – May 2018) Texas opioid-related health care utilization

University of California, San Francisco

PharmD students

1. Sherry Kwon (Sep 2011 – Dec 2011) Decision analysis of abiraterone and cabazitaxel in treatment castration-resistant prostate cancer
2. Meghan Frear (Sep 2011 – Dec 2011) Decision analysis of abiraterone and cabazitaxel in treatment castration-resistant prostate cancer
3. Nicole Nguyen (Sep 2011 – Dec 2011) Decision analysis of abiraterone and cabazitaxel in treatment castration-resistant prostate cancer
4. Vickie Pon (Sep 2011 – Dec 2011) Decision analysis of abiraterone and cabazitaxel in treatment castration-resistant prostate cancer

Duke University

Undergraduate students

1. Nick Schwartz (Jun 2009 – May 2011) Egg laying behavior in *Drosophila melanogaster*
2. Yifan Xu (Jun 2007 – May 2008) Nociception in *Drosophila* larvae
3. James Friedman (Jun 2008 – May 2009) Optogenetic control of nociceptive behavior in *Drosophila* larvae

INSTITUTIONAL AND PROFESSIONAL ACTIVITIES/SERVICES

University/College/Department:

Current

2021-2023: **Co-chair**, Self-Study Assessment & Planning Sub-committee, Rangel College of Pharmacy

2020- present: **Chair for Ad hoc Co-curricular Committee**, Rangel College of Pharmacy, Texas A&M University Health Science Center

2020- present: **Research Mentor**, Medical Scholar research Pathway Program, Texas A&M University

2018 - present: **Faculty sponsor** for student ambassadors for opioid research, Texas A&M University Health Science Center

05/2018 - present: **Member**, Opioid Task Force, Texas A&M University Health Science Center

2017- present: **Faculty Advisor** for ISPOR Student Chapter at Texas A&M University

2017- present: **Steering Committee Member**, Women's Faculty Network (WFN), Texas A&M University

2017- present: **Treasurer**, Women's Faculty Network (WFN), Texas A&M University

2015- present: **Faculty advisor**, Rangel College of Pharmacy

2015 - present: **Member**, Awards, Honors and Fellowship Committee, Rangel College of Pharmacy, Texas A&M University Health Science Center

Completed:

05/2022: **Member**, Postdoctoral fellow Achievement Award Selection Committee
05/2022: **Faculty interviewer**, COP Class 2022 Pharm.D. Graduate Exit Interview
04/2022: **Faculty judge**, 2022 Medical Research Colloquium, College of Medicine, Texas A&M University
02-05/2022: **Member**, Search Committee for COP (SAS faculty)
2021 Nov- 2022 Feb: **Interim Faculty Secretary**, Rangel College of Pharmacy
2021 Nov- 2022 Feb: **Interim Chair for Awards, Honors & Scholarships Committee**, Rangel College of Pharmacy
2019-2021 **Faculty Secretary**, Rangel College of Pharmacy, Texas A&M University Health Science Center
05/2021: **Faculty interviewer**, COP Class 2021 Pharm.D. Graduate Exit Interview
2020- 2021: **Member**, Faculty Grievance Committee, Rangel College of Pharmacy, Texas A&M University
09/2020- 05/2021: **PCSI representative**, Research Elective Track Task Force, Rangel College of Pharmacy
07/2020: **Organizer**, Faculty strategic planning retreat, Rangel College of Pharmacy
05/2020: **Faculty interviewer**, COP Class 2020 Pharm.D. Graduate Exit Interview
05/2019: **Faculty interviewer**, COP Class 2019 Pharm.D. Graduate Exit Interview
01/2019: **Faculty judge**, AMCP Foundation 2018 P&T Competition, Rangel College of Pharmacy, Texas A&M University Health Science Center
06/2018: **Chair**, Award Selection Committee for the Association of Former Students Distinguished Achievement Award College-Level Teaching Award, Rangel College of Pharmacy, Texas A&M University
2017- 2018: **Member**, Faculty Grievance Committee, Rangel College of Pharmacy, Texas A&M University
09/2015 to 05/2018: **Member**, Research Advisory *ad hoc* Committee, Rangel College of Pharmacy, Texas A&M University Health Science Center
03/2018- 05/2018: **Member**, MALTO Conference Planning Committee, Rangel College of Pharmacy, Texas A&M University
2018: **Member**, the Center for Microencapsulation and Drug Delivery (CMDD), Texas A&M University Health Science Center
01/2018: **Faculty judge**, AMCP Foundation 2018 P&T Competition, Rangel College of Pharmacy, Texas A&M University Health Science Center
01/2017: **Faculty judge**, AMCP Foundation 2017 P&T Competition, Rangel College of Pharmacy, Texas A&M University Health Science Center
2016-2018: **Member**, *ad hoc* Graduate Program Committee (GPC), Rangel College of Pharmacy, Texas A&M University Health Science Center

09/2016 to 05/2016: **Member**, Master Program Committee, Rangel College of Pharmacy, Texas A&M University Health Science Center

04/2016: **Faculty facilitator**, the College of Pharmacy OSCE II, Rangel College of Pharmacy, Texas A&M University Health Science Center

11/2015 to 05/2016: **Member**, Physiologist Search Committee, Department of Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M University Health Science Center

11/2015: **Faculty judge**, Student HPHD poster presentation, Rangel College of Pharmacy, Texas A&M University Health Science Center

PharmD Student Advisees

2016-2018 (Class 2019, P1-P3 year)	2019-2022 (Class 2023, P1-P3 year)
Janson Rector	David Dodge
Binamra Newpane	Emily Wong
Jane Ijoma	Isela Gonzalez
Jennifer Nguyen	Ishimwe Masozera
Kallen Vann	Kelly Ramsey
Lauren Black	Kevin Berrios
Tam Ngac	Liam Ha
Tanner Dodd	Bethany Davis
Thao Tran	

PROFESSIONAL SERVICE:

2018-2019: Grant reviewer for Texas Society of Health-System Pharmacists (TSHP)

2017- present: Faculty Advisor at International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Faculty Advisor Council

2017- present: Faculty Advisor, Student Chapter for International Society of Pharmacoeconomics and Outcomes Research (ISPOR) at Texas A&M University

2018: Reviewer for Issue Panel, ISPOR 8th Asia-Pacific Conference

2017: Reviewer for Research Abstract, ISPOR 19th European Congress

2016: Reviewer for Research Abstract, ISPOR 7th Asia-Pacific Conference

Ad hoc reviewer for *Journal of Managed Care and Specialty Pharmacy*

Ad hoc reviewer for *Journal of Medical Economics*

Ad hoc reviewer for *Journal of Research in Social and Administrative Pharmacy*

Ad hoc reviewer for *Frontiers in oncology*

Ad hoc reviewer for *Journal of ClinicoEconomics and Outcomes Research*

Ad hoc reviewer for *Risk Management and Healthcare Policy*

Ad hoc reviewer for *Journal of National Cancer Institute*

Ad hoc reviewer for *Journal of Alzheimer Disease & Associated Disorders*

Ad hoc reviewer for *Journal of Neuroscience*

Ad hoc reviewer for *Pain*

Ad hoc reviewer for *PLoS ONE*

Ad hoc reviewer for *Molecular Neuroscience*

Ad hoc reviewer for *Insect Biochemistry and Molecular Biology*